Do analysts rate ANIX or PYRGF?

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 145.66%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anixa Biosciences is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer ANIX or PYRGF?

In the previous week, Anixa Biosciences had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for PyroGenesis Canada. Anixa Biosciences' average media sentiment score of 1.29 beat PyroGenesis Canada's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ENGN or PYRGF?

enGene presently has a consensus price target of $11.05, indicating a potential upside of 527.58%. Given enGene's stronger consensus rating and higher possible upside, equities research analysts clearly believe enGene is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer ENGN or PYRGF?

In the previous week, enGene had 8 more articles in the media than PyroGenesis Canada. MarketBeat recorded 9 mentions for enGene and 1 mentions for PyroGenesis Canada. enGene's average media sentiment score of 0.42 beat PyroGenesis Canada's score of 0.00 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PYRGF or IFRX?

InflaRx has a consensus price target of $7.00, suggesting a potential upside of 311.76%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Do analysts recommend VTVT or PYRGF?

vTv Therapeutics currently has a consensus price target of $56.67, indicating a potential upside of 82.68%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe vTv Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to VTVT or PYRGF?

In the previous week, vTv Therapeutics had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for vTv Therapeutics and 1 mentions for PyroGenesis Canada. vTv Therapeutics' average media sentiment score of 1.27 beat PyroGenesis Canada's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PYRGF or SPRB?

Spruce Biosciences has a consensus target price of $162.63, suggesting a potential upside of 287.29%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Does the media favor PYRGF or SPRB?

In the previous week, Spruce Biosciences had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for PyroGenesis Canada. Spruce Biosciences' average media sentiment score of 0.88 beat PyroGenesis Canada's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PyroGenesis Canada (PYRGF) Competitors

$0.13 0.00 (-0.90%)

As of 12:43 PM Eastern

Compare

PYRGF vs. ANIX, ENGN, IFRX, VTVT, and SPRB

Should you buy PyroGenesis Canada stock or one of its competitors? MarketBeat compares PyroGenesis Canada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PyroGenesis Canada include Anixa Biosciences (ANIX), enGene (ENGN), InflaRx (IFRX), vTv Therapeutics (VTVT), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry.

How does PyroGenesis Canada compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Anixa Biosciences has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
PyroGenesis Canada	-115.14%	N/A	-60.81%

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Anixa Biosciences has higher earnings, but lower revenue than PyroGenesis Canada. Anixa Biosciences is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	560.52	-$10.93M	-$0.31	N/A
PyroGenesis Canada	$9.14M	3.53	-$21.12M	-$0.04	N/A

In the previous week, Anixa Biosciences had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for PyroGenesis Canada. Anixa Biosciences' average media sentiment score of 1.29 beat PyroGenesis Canada's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 145.66%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anixa Biosciences is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Anixa Biosciences has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Summary

Anixa Biosciences beats PyroGenesis Canada on 11 of the 17 factors compared between the two stocks.

How does PyroGenesis Canada compare to enGene?

enGene (NASDAQ:ENGN) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

64.2% of enGene shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PyroGenesis Canada has higher revenue and earnings than enGene. PyroGenesis Canada is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
PyroGenesis Canada	$9.14M	3.53	-$21.12M	-$0.04	N/A

In the previous week, enGene had 8 more articles in the media than PyroGenesis Canada. MarketBeat recorded 9 mentions for enGene and 1 mentions for PyroGenesis Canada. enGene's average media sentiment score of 0.42 beat PyroGenesis Canada's score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

enGene has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

enGene presently has a consensus price target of $11.05, indicating a potential upside of 527.58%. Given enGene's stronger consensus rating and higher possible upside, equities research analysts clearly believe enGene is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

enGene has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

enGene beats PyroGenesis Canada on 9 of the 15 factors compared between the two stocks.

How does PyroGenesis Canada compare to InflaRx?

PyroGenesis Canada (NASDAQ:PYRGF) and InflaRx (NASDAQ:IFRX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

InflaRx has a consensus price target of $7.00, suggesting a potential upside of 311.76%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

InflaRx has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
InflaRx	N/A	-88.30%	-65.77%

PyroGenesis Canada has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PyroGenesis Canada has higher revenue and earnings than InflaRx. PyroGenesis Canada is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.53	-$21.12M	-$0.04	N/A
InflaRx	$30K	4,096.43	-$51.63M	-$0.71	N/A

In the previous week, PyroGenesis Canada and PyroGenesis Canada both had 1 articles in the media. InflaRx's average media sentiment score of 1.87 beat PyroGenesis Canada's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
InflaRx	Very Positive

Summary

InflaRx beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

vTv Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. vTv Therapeutics' return on equity of 3.96% beat PyroGenesis Canada's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
PyroGenesis Canada	-115.14%	N/A	-60.81%

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, vTv Therapeutics had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for vTv Therapeutics and 1 mentions for PyroGenesis Canada. vTv Therapeutics' average media sentiment score of 1.27 beat PyroGenesis Canada's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	119.82	-$26.97M	-$0.93	N/A
PyroGenesis Canada	$9.14M	3.53	-$21.12M	-$0.04	N/A

vTv Therapeutics currently has a consensus price target of $56.67, indicating a potential upside of 82.68%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe vTv Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

vTv Therapeutics beats PyroGenesis Canada on 11 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to Spruce Biosciences?

PyroGenesis Canada (NASDAQ:PYRGF) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PyroGenesis Canada has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Spruce Biosciences. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.53	-$21.12M	-$0.04	N/A
Spruce Biosciences	$4.91M	23.52	-$38.97M	-$36.60	N/A

Spruce Biosciences has a consensus target price of $162.63, suggesting a potential upside of 287.29%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Spruce Biosciences has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Spruce Biosciences	N/A	-155.40%	-101.67%

In the previous week, Spruce Biosciences had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for PyroGenesis Canada. Spruce Biosciences' average media sentiment score of 0.88 beat PyroGenesis Canada's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spruce Biosciences beats PyroGenesis Canada on 10 of the 16 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceutical Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$32.51M	$955.18M	$9.42B	$12.18B
Dividend Yield	N/A	4.84%	3.49%	9.42%
P/E Ratio	-2.20	1.51	27.03	23.74
Price / Sales	3.53	109.27	1,944.73	94.28
Price / Cash	N/A	22.05	27.03	46.67
Price / Book	-13.19	8.47	4.41	6.16
Net Income	-$21.12M	-$3.38M	$792.89M	$331.26M
7 Day Performance	-0.08%	-0.55%	0.74%	-0.06%
1 Month Performance	-8.78%	-5.50%	0.51%	-2.52%
1 Year Performance	-55.44%	27.20%	13.16%	13.95%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.13 -0.9%	N/A	-55.0%	$32.51M	$9.14M	N/A	90	News Coverage Gap Down
ANIX Anixa Biosciences	4.4579 of 5 stars	$3.70 -1.3%	$8.50 +129.7%	+14.9%	$127.59M	N/A	N/A	5	Positive News
ENGN enGene	3.3106 of 5 stars	$1.82 -3.7%	$11.05 +506.9%	-50.8%	$126.60M	N/A	N/A	31	Analyst Downgrade
IFRX InflaRx	2.8142 of 5 stars	$1.74 +0.6%	$7.00 +302.3%	+93.6%	$125.07M	$29.33K	N/A	60
VTVT vTv Therapeutics	3.3051 of 5 stars	$30.73 -2.9%	$56.67 +84.4%	+99.2%	$124.71M	$1.02M	N/A	9	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. ANIX, ENGN, IFRX, VTVT, and SPRB

How does PyroGenesis Canada compare to Anixa Biosciences?

Summary

How does PyroGenesis Canada compare to enGene?

Summary

How does PyroGenesis Canada compare to InflaRx?

Summary

How does PyroGenesis Canada compare to vTv Therapeutics?

Summary

How does PyroGenesis Canada compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. ANIX, ENGN, IFRX, VTVT, and SPRB

How does PyroGenesis Canada compare to Anixa Biosciences?

Is ANIX or PYRGF more profitable?

Do institutionals and insiders hold more shares of ANIX or PYRGF?

Which has better earnings & valuation, ANIX or PYRGF?

Does the media prefer ANIX or PYRGF?

Do analysts rate ANIX or PYRGF?

Which has more risk & volatility, ANIX or PYRGF?

Summary

How does PyroGenesis Canada compare to enGene?

Do insiders and institutionals have more ownership in ENGN or PYRGF?

Which has higher earnings and valuation, ENGN or PYRGF?

Does the media prefer ENGN or PYRGF?

Which has more volatility & risk, ENGN or PYRGF?

Do analysts rate ENGN or PYRGF?

Is ENGN or PYRGF more profitable?

Summary

How does PyroGenesis Canada compare to InflaRx?

Do analysts rate PYRGF or IFRX?

Is PYRGF or IFRX more profitable?

Which has more volatility and risk, PYRGF or IFRX?

Do insiders & institutionals hold more shares of PYRGF or IFRX?

Which has stronger earnings and valuation, PYRGF or IFRX?

Does the media prefer PYRGF or IFRX?

Summary

How does PyroGenesis Canada compare to vTv Therapeutics?

Is VTVT or PYRGF more profitable?

Do institutionals and insiders believe in VTVT or PYRGF?

Does the media refer more to VTVT or PYRGF?

Which has more risk & volatility, VTVT or PYRGF?

Which has preferable earnings & valuation, VTVT or PYRGF?

Do analysts recommend VTVT or PYRGF?

Summary

How does PyroGenesis Canada compare to Spruce Biosciences?

Do institutionals and insiders hold more shares of PYRGF or SPRB?

Which has more volatility and risk, PYRGF or SPRB?

Which has preferable valuation & earnings, PYRGF or SPRB?

Do analysts recommend PYRGF or SPRB?

Is PYRGF or SPRB more profitable?

Does the media favor PYRGF or SPRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools